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Determining Mechanisms of Response to Polo-like Kinase 1 Inhibition in Non-Small Cell Lung 
Cancer 
Ruchitha Goonatilake, B.S. 
Supervisory Professor: Faye M. Johnson, M.D., Ph.D.  
 
Non-small c ell l ung c ancer ( NSCLC) i s the l eading c ause o f c ancer-related deat h 
worldwide. The discovery of genetic alterations in some patients (~15%) has made it possible to 
use targeted therapies without the use of chemotherapy. To identify potential therapeutic targets 
in NSCLC, we systematically evaluated two cancer cell line databases with sensitivity data for a 
broad range of drugs. We identified polo-like kinase 1 (Plk1) as the most promising target for 
further i nvestigation ba sed on a s ubset o f s ensitive c ell l ines and i nhibitors t hat w ere i n 
advanced clinical development. 
To identify potential biomarkers of response and mechanisms of Plk1 inhibitor-
induced apoptosis, we performed an i ntegrated analysis of  gene and pr otein expression, gene 
mutation, and dr ug sensitivity using three Plk1 inhibitors (volasertib, BI2536, GSK461364) in a 
large panel  o f N SCLC c ell l ines.  We obs erved t hat t he N SCLC c ell l ines ha ve v arying 
sensitivities t o P lk1 in hibition, w ith a  s maller subset de monstrating s ensitivity t o al l t hree 
inhibitors.  Plk1 inhibition led to increase of cells with 4N DNA content, but only sensitive cell 
lines underwent substantial apoptosis following Plk1 inhibition. NSCLC lines with a high 
epithelial-mesenchymal t ransition gene signature s core (i.e., mesenchymal l ines) w ere m ore 
sensitive to Plk1 inhibitors than epithelial lines (p<0.02).  Similarly, proteomic profiling 
demonstrated that E-cadherin expression was higher in the resistant cell lines (p<0.01).  
Induction o f an epi thelial phenot ype us ing miR-200 ex pression i ncreased r esistance t o P lk1 
inhibition, w hereas ex pression o f ZE B1 i ncreased s ensitivity t o P lk1 i nhibition. A dditionally, 
treatment o f with TGF-β to induce EMT sensitized a resistant cell line and led to increased 
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apoptosis a fter P lk1 i nhibition, c ompared t o par ental c ells. KRAS mutation and a lterations i n 
tight-junction, ErbB, and Rho signaling pathways also correlated with drug response.   
We dem onstrate t hat epi thelial-mesenchymal t ransition l eads to P lk1 i nhibitor 
sensitivity in  a  la rge-scale, i ntegrated anal ysis o f P lk1 i nhibitor sensitivity.  O ur findings have 
important clinical implications for mesenchymal NSCLC, as a s ignificant subset of this disease 
associated with resistance to currently approved targeted therapies.   
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Lung Cancer 
Lung cancer is the deadliest cause of cancer in the world, with estimates 
approximating more than 200,000 deaths in the United States alone for 2015 (1). Lung 
cancer is usually split into two main categories: non-small cell lung cancer (NSCLC) and 
small cell lung cancer (SCLC).  NSCLC makes up approximately 85% of all lung cancer 
cases whereas SCLC makes up 15% (1) Most of the lung cancer cases are attributed to 
tobacco use. However, there are a host of other factors which may contribute, including 
environmental causes, such as exposure to secondhand smoke, air pollution, inherited 
factors, , and other substances (2-4). Lung cancer is not frequently found in people 
under 35, and the incidence of lung cancer rises exponentially afterwards (5). Although 
there have been great advances in terms of early detection and treatment, most new 
cases are usually found at late stages and are resistant to therapy (6). The five-year 
survival rate for all stages of lung cancer is 54% for localized disease, but decreases to 
4% in cases of distant metastasis (1, 7). 
 
Non-small cell lung cancer 
 NSCLC is made up of three major histologies:  squamous cell carcinoma (SCC), 
large cell carcinoma, and adenocarcinoma. There are several other histologies which 
occur much less frequently. Adenocarcinoma accounts for approximately 50% of 
NSCLC, and usually originates in the more peripheral regions of the lungs (8). Although 
adenocarcinoma is associated with tobacco use, it is more common in the non-smoking 
population than other subtypes (9). Another major histology of NSCLC is the squamous 
cell carcinoma which originates from the proximal airway. SCC accounts for 
18 
 
approximately 35% of NSCLC, and 11% are accounted for by large cell carcinoma, 
originating from the bronchi located more towards the center of the lungs (8).    
 
Common genetic aberrations in NSCLC 
 The development of tumors is not a single step process; on the contrary, it is a 
complex process which occurs due to the accumulation of several genetic alterations 
over a period of time (10). These accumulating alterations allow for cancer cells to have 
advantages in growth and survival compared to normal cells. Genetic aberrations have 
been characterized in NSCLC which contribute to various advantages in proliferation, 
survival, migration, invasion, and resistance to programmed cell death - all hallmarks of 
cancer (11). The most frequent aberrations in adenocarcinoma include mutations in 
Kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor 
(EGFR), met proto-oncogene (MET), LKB1 (serine/threonine kinase 11), and TP53 (12). 
EGFR gene amplification is seen in around 15% of patients while MET amplification is 
seen in approximately 20% of adenocarcinoma patients (12). In the squamous cell 
carcinoma, mutations which frequently occur also include MET, TP53, LKB1, and 
KRAS. EGFR and MET amplification are seen in 30% and 21% of SCCs and EGFR 
mutations are rare (12). Other aberrations which have been found in NSCLC at lower 
frequencies include BRAF mutations, HER2 mutations, TITF-1 amplification, and ALK 
translocations (13).  
 
Treatment of NSCLC 
 Patients diagnosed with early stages of disease usually undergo surgery and 
adjuvant chemotherapy may allow for more beneficial results with resected tumors (4). 
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Patients with locally advanced disease are treated with chemotherapy and radiation in 
conjunction, either with or without surgery (14). Patients with metastatic disease are 
usually treated with palliative chemotherapy (14). Chemotherapy usually is made up of 
platinum based compounds which are combined with other  cytotoxic agents such as 
taxanes or pemetrexed (8).  
 Treatments targeting a specific oncogenic driver molecule based on genetic 
alterations have recently been developed for NSCLC. An example of these targeted 
therapies are the EGFR tyrosine kinase inhibitors, which have resulted in significant 
improvements in response rates and progression-free survival for subsets of patients 
with these genetic alterations (15). Another example is the development of anaplastic 
lymphoma kinase (ALK) inhibitors for NSCLC patients with EML4-ALK translocations.  
ALK and EGFR inhibitors are currently approved for use in NSCLC patients with 
metastatic cancer (16). Despite these promising results, some patients do not respond 
to the inhibitors and nearly all who initially respond develop resistance (15).  
 
Hallmarks of cancer 
 Cancer development is a complex process in which cancer cells must overcome 
many obstacles to thrive. Their genomes are changed at several stages through 
mutations, amplification, deletion and other mechanisms. Douglas Hanahan and Robert 
Weinberg proposed that the diversity of cancer genotypes is a result of eight essential 
physiological alterations: evading apoptosis, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, sustained angiogenesis, limitless replicative 
potential, tissue invasion & metastasis, abnormal metabolic pathways, and evading the 
immune system (10).  These hallmarks are novel capabilities that cells acquire during 
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tumorigenesis, that enable them to overcome anticancer mechanisms which have been 
programmed into cells.  
 In addition to breaking through the physiological barriers through acquisition of 
these hallmarks, cancer is viewed as a disease of the cell cycle (17). This is due to the 
fact that cells undergo disruptions which can affect the cell cycle machinery which leads 
to the increased or inappropriate proliferation, a major hallmark of cancer. These 
defects can target the cell cycle itself or upstream signaling which has consequences in 
the cell cycle.  
 
Phases of the cell cycle 
 The eukaryotic process of cell division known as mitosis has been well studied 
(18). Eukaryotic cells follow a program to divide and proliferate called the cell cycle; this 
process can be divided into three phases: interphase, mitotic (M) phase, and 
cytokinesis. In interphase, the cell grows, duplicates its DNA content, and obtains the 
necessary nutrients for the ensuing division. In the M phase, the cell divides into two 
daughter cells. This process is finalized in the cytokinesis. To make sure cells divide 
correctly, there are control mechanisms termed the cell cycle checkpoints. 
 Nonproliferating cells are thought to be in the G0 phase. Here, the cells are able 
to remain quiescent for a long interval of time. Senescent cells enter this phase 
permanently in response to DNA damage or degradation (19). Interphase of the cell 
cycle consists of three subphases, Gap 1 (G1), S, and Gap 2 (G2). Interphase consists 
of about 90% of the total time necessary for the cell cycle process (20). The G1 phase 
is the interval  between the M phase of the previous cycle to S phase of the subsequent 
cycle. Here, the cells need to acquire the necessary nutrients to be able to sustain 
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themselves during the cell cycle. The ensuing S phase begins as the DNA replication 
starts; it is completed once all the chromosomes have replicated resulting in two sister 
chromatids. After the S phase is properly completed, the G2 phase of interphase 
occurs. The G2 phase is often characterized by quick cell growth and the synthesis of 
various proteins essential for cell division (21).  
After the G2 phase, the relatively short M phase begins. In the M phase, the cell 
separates its chromosomes into two separate nuclei. Chromosomes condense and are 
pulled apart by cellular machinery to opposite parts of the cell. The nuclear envelope 
forms around the chromosomes, and begins forming the two identical daughter cells. 
The M phase consists of four stages: prophase, prometaphase/metaphase, anaphase, 
and telophase. Prophase is the beginning of mitosis, where the nuclear envelope 
breaks down, and condensed chromosomes start to appear, consisting of two sister 
chromatids which have been produced during the S phase. Additionally, the duplicated 
centrosomes move towards the opposite sides of the nucleus and will be the two poles 
of the mitotic spindle. In prometaphase the microtubules of the spindle attach to the 
kinetochores of the chromosomes. The kinetochores of the sister chromatids are 
located on both sides of each chromosome, so the microtubules from the two sides of 
the spindle will be able to attach. During metaphase the condensed chromosomes then 
align at the equatorial plate of the dividing cell known as the metaphase plate. In 
anaphase the sister chromatids break apart and move towards the opposite sides of the 
mitotic spindle. The last step is telophase, where the nuclei form again and the 
chromosomes decondense.  The process is then followed by cytokinesis, a process in 
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which the nuclei, organelles and other features are equally distributed to the two 
identical daughter cells which will be in interphase (21).   
Many checkpoints exist so that damaged or incomplete DNA is not taken up by 
the daughter cells. The main checkpoints that exist in the cell cycle are the G1/S, G2/M, 
and M checkpoints. The G1/S checkpoint is the rate-limiting and most important step in 
the cell cycle; it is known as the restriction point (21). The stages of the cell cycle are 
regulated by several proteins discussed in the next section. 
 
Cyclins, CDKs, and Mitotic Entry 
Two kinds of regulatory proteins are in charge of the cell’s progress in the cell 
cycle: these are the cyclins and the cyclin-dependent kinases (CDKs). Together the two 
components form heterodimers where the cyclins are the regulatory subunit and the 
CDK is the catalytic subunit (17). Cyclins do not have catalytic activity on their own, 
whereas CDKs are inactive without the cyclin subunit. When the cyclin binds to the 
CDK, they phosphorylate downstream signaling and either activate or inactivate 
downstream targets to control the progression to different phases of the cycle.  
Eukaryotic cells have nine CDKs, of which five have direct involvement in the cell 
cycle(17). In mammals, CDK1 and its binding cyclin partners A2 and B are enough to 
drive the cell cycle. Cyclin-CDK complexes involved in earlier cell-cycle phases are 
needed to activate complexes in later phases. Each phase of the cell cycle is governed 
by the complexes of different cyclins and CDKs as shown in Table 1. 
 
 
23 
 
Phase Cyclin CDK 
G0 C CDK3 
G1 D, E CDK4, CDK2, CDK6 
S A, E CDK2 
G2 A CDK2, CDK1 
M B CDK1 
 
Table 1. Cyclin-CDK complexes involved in the phases of the cell cycle. 
 
 
The entry into mitosis is regulated by the CDK1-cyclin B complex (22). Normal 
cells usually have low cyclin B expression when the S phase begins and the levels 
increase at the end of G2. Cyclin B levels are regulated by several transcription factors, 
including p53, p21, and c-Myc. These transcription factors allow for the accumulation of 
CDK1-cyclin B complex. Near the end of the G2 phase, the complex is inactivated due 
to inhibitory phosphorylation of CDK1 by Wee1 (Tyr15) and Myt1 (Thr14 and Tyr15). 
Cdc25 phosphatases dephosphorylate these sites to activate the CDK1-cyclin complex 
(17). Inhibition of the Wee1 and Myt1 kinases induce mitotic entry of cells which have 
been arrested in the S phase (23, 24).  
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Plk family 
In addition to the cyclin-CDK complexes, polo-like kinases play a major role in 
cell cycle progression and control. The founding member of the family is the polo gene 
that was first discovered and characterized in drosophila mutants with spindle pole 
defects (25). After these findings, Plks have been characterized in eukaryotic cells. The 
Plk family consists of five known members: Plk1, 2, 3, 4, and 5. 
All Plk family members have the same basic structure, consisting of a 
serine/threonine kinase domain at the amino terminus, and a regulatory portion, 
consisting of the polo boxes in the carboxyl terminus as seen in Figure 3 (25, 26).  The 
Plk family members have either one (Plk5) or 2 (Plk1,2,3) or 3 (Plk4) polo-boxes. 
 
 
Figure 1. Structure of Plk. The structure of Plks consist of the kinase domain and the 
polo-box domain, containing one or more polo boxes, connected by a linker.   Reprinted 
by permission from Macmillan Publishers Ltd: Nature Reviews: Molecular Cell Biology, 
Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. 
Nature reviews Molecular cell biology. 2004;5(6):429-40. 2004. (25) 
 
The kinase domain is evolutionarily conserved among all members of the Plk 
family. The unique feature of the Plk family is the complex of polo boxes, called the polo 
box domain (PBD).  The PBD binds to a serine or threonine site that has been 
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phosphorylated by another kinase or by a Plk itself – a process called priming.  
Additionally, the PBD can bind to non-phosphorylated peptides such as Map205 (27). 
Of the Plk family members Plk1 is the best characterized member, whereas the 
functions of Plk2, 3, and 4 are not as well understood. In humans, Plk1 has been 
primarily linked to the regulation of different events, mostly with the proper entry into 
mitosis, the spindle assembly, and cytokinesis. Plk1 has also functions in the DNA 
damage checkpoints (28). Plk2 is known as a tumor suppressor which functions in 
centriole duplication and progression in G1-S of the cell cycle (29). Plk3 is known to 
regulate the cell cycle, responses to various stresses, and disassembly of the Golgi 
apparatus (30). Additionally Plk3 has tumor suppressor functions as well. Plk4 is also 
known to function in centriole duplication and has regulatory roles in mitosis (31). 
Recently, Plk5 has also been found which has lower catalytic activity, but has significant 
functions in neurons (32). 
A systematic evaluation of two screening databases, the Cancer Cell Line 
Encyclopedia (CCLE), and Genomics of Drug Sensitivity to Cancer (GDSC) led to the 
identification of Plk1 as a promising target for further investigation (33, 34). Plk1 
emerged as the top candidate based on specific criteria: inhibition of the target must be 
highly effective in a subset of NSCLC cell lines, the target should not extensively 
studied in NSCLC, and the target must have inhibitors in development for potential 
translational studies. Studies in non-selected, refractory NSCLC patients showed 4% 
derived a significant benefit from Plk1 inhibitors (35). However, it is unclear why a small 
subset of patients respond to Plk1 inhibitors. We sought to further investigate the effect 
of Plk1 inhibition on NSCLC cell lines. 
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Plk1 regulation 
The activities of Plks are regulated by localization, phosphorylation and relative 
abundance. For example, during prophase and metaphase, Plk1 is localizes to the 
centrosomes and kinetochores, where it functions in the maturation of the centrosomes 
and the spindle assembly checkpoint (36). Regulation  primarily occurs through the 
phosphorylation of target proteins involved in these pathways. The polo box domain is 
crucial for Plk1 localization and activity, as mutations in residues have demonstrated 
inability for Plk1 to localize to the spindle poles (32). 
Plk1 is expressed from G2 to the end of mitosis when it is rapidly degraded.  Plk1 
has a short half-life, and is expressed from G2 to the end of mitosis when it is rapidly 
degraded during anaphase. The degradation of Plk1 is triggered by APC/C (26). 
Plk1 transcription is repressed during G1 and activated in G2 (26). RB and E2F 
transcription factors repress Plk1 transcription.  The DREAM complex and FOXM1 
promote Plk1 transcription (26). 
The kinase activity of Plk1 is observed mainly in the G2-M transition and peaks 
during the M phase (25). Post-translational modification (phosphorylation) is reported to 
be a major regulatory mechanism for Plk1. Phosphorylation of Plk1 results in its 
activation. The activation of Plk1 has been proposed to work through priming 
phosphorylation of binding partners by the CDK1-cyclin B complex which allows for the 
binding of the PBD thereby uncoupling it from the kinase domain (37). It has been 
reported in human cells that Plk1 activation occurs a few hours before entry into the 
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mitotic phase (27). Phosphorylation of Ser128 (hinge region) and Thr210 (T loop) are 
required for activity.  Aurora A and its co-factor Bora phosphorylate Plk1at Thr210 (26). 
This phosphorylation is a crucial step for Plk1 to start mitotic entry and in promoting 
mitosis after G2 checkpoint arrest.  
 
Plk1 and mitotic entry 
One of the main functions of Plk1 is to facilitate mitotic entry. Mitotic entry is 
regulated by the levels of the active CDK1-cyclin B complex. In G2, there is increased 
activity of the cyclin B promoter and more stabilization of cyclin B mRNA levels as 
compared to other phases of the cell cycle, leading to higher levels of protein (38). 
Cyclin B is able to bind to the inactive CDK1, but the complex is initially inactive due to 
phosphorylation by Wee1 and Myt1 (Fig. 4). 
 
 
Figure 2. Role of Plk1 in Mitotic Entry. Plk1 facilitates mitotic entry by acting on 
several substrates including cyclin B, Wee1, Myt1, and Cdc25. Reprinted by permission 
from Macmillan Publishers Ltd: Oncogene, van Vugt MA, Medema RH. Getting in and 
out of mitosis with Polo-like kinase-1. Oncogene. 2005;24(17):2844-59. 2005.(39) 
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CDK1 is phosphorylated by the Wee1 and Myt1 kinases on the ATP binding site 
of Tyr15 and by Myt1 on Thr14. This phosphorylation prevents ATP from binding and 
the transfer of the phosphate group for the kinase activity (39). Additionally, the complex 
is regulated by the localization within the cell. For entry into mitosis, dephosphorylation 
of the sites on the CDK1-cyclin B complex is crucial for complex activation. The 
dephosphorylation is done by the members of the Cdc25 family of phosphatases (a, b, 
and c). Plk1 regulates the activity of the Wee1 and Myt1 kinases along with the Cdc25c 
phosphatase. Plk1 phosphorylates Myt1 and Wee1, primarily to inhibit them and also 
marks Wee1 for degradation (39). Plk1 activates Cdc25c, promoting the activity of the 
CDK1-cyclin B complex.  
 
Plk1 and DNA damage response 
Additionally, Plk1 plays a role in the DNA damage response. When DNA damage 
occurs, cells are unable to proceed in mitosis until the DNA is repaired– a process 
termed the G2 DNA damage checkpoint (28). Inactivation of Plk1 is a key mediator of 
this G2 arrest. Before entry into mitosis, Plk1 is phosphorylated by Aurora A kinase 
together with Bora, at the Thr210 site, activating it. Bora is able to open up the closed 
formation of Plk1 and Aurora A is able to phosphorylate Plk1 for activation during the 
mitotic entry. In response to the DNA damage, two kinases : ATM  (ataxia talangectasia 
mutated) and ATR (ATM and RAD3-related) are activated. ATM and ATR phosphorylate 
Bora at Thr 501, causing it to be recognized by the E3 ubiquitin ligase for degradation 
(28). Once degraded, however, Bora cannot facilitate the activation of Plk1 (28). As Plk1 
is not able to be activated, CDK1 is unable to be activated, resulting in a G2 arrest. 
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When DNA damage occurs in cells at the G2 phase, they avoid production of abnormal 
chromosomes by not going into mitosis. Following DNA repair, Plk1 is again activated, 
allowing for the mitotic entry and recovery of cell division.   
 
Plk1 and the spindle assembly checkpoint (SAC) 
The SAC is a process which ensures that the kinetochores of the chromosomes 
are properly attached to spindle microtubules for proper cell division. It prevents the 
start of anaphase until all kinetochores are attached properly to the microtubules 
coming from the poles from the opposite sides of the parental cell (40). Plk1 functions to 
relieve the inhibitory signal of the spindle checkpoint.  During meta- and anaphase, Plk1 
is localized to the chromatids, where it is required for stable attachment of kinetochores 
to the microtubules of the spindle apparatus (36). Plk1 depleted cells which are also co-
depleted of surviving are not able to arrest, suggesting that Plk1 is crucial to producing 
the tension on the kinetochores to start the spindle checkpoint signaling (41). 
Additionally, Plk1 is known to phosphorylate the translationally controlled tumor 
protein (TCTP) at Ser46 (42). TCTP is a highly expressed protein which is known to 
have a function in a variety of cellular processes, one of which is stabilization of 
microtubules (43). It is known to localize with other factors towards the spindle during its 
assembly (44). Checkpoint proteins, including Mad and Bub and Mps1 kinase 
negatively regulate the activity of the Anaphase-Promoting Complex (APC) by 
inactivating Cdc20. Once the kinetochores and microtubules are properly attached, 
these signals will deteriorate and the APC will activate. The degradation of securin, 
which normally binds and inhibits the protease, separase, is an important step in 
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promoting anaphase (45). Separase, which is now active, then cleaves the Scc1 (sister-
chromatid cohesion-1) subunit of the cohesin complex, which results in the loss of 
sister-chromatid cohesion. The chromatids now are able to separate in the anaphase 
stage. The Cdc20 form of APC also targets cyclin B for degradation, leading to the 
inactivation of CDK1 (36).  
 
Plk1 in cancer 
Plk1 was first reported to be associated with neoplastic growth based on studies 
showing increased levels of Plk1 expression are increased in cancer. Plk1 is 
overexpressed in different types of cancers including NSCLC, melanoma, colon, and 
prostate cancers (46). While the expression of Plk1 is below the limit of detection in 
most adult tissues, organs with an increased population of proliferative cells, such as 
the thymus, spleen and testes, express detectable Plk1 at low concentrations (46). Plk1 
overexpression leads to oncogenesis by causing chromosomal instability and other 
aberrations in mitosis caused by checkpoint defects. Plk1 overexpression has also been 
reported to transform NIH 3T3 cells in vitro and in vivo (47).  
 
Plk1 inhibitors in cancer 
Given its apparent role in neoplasias, several inhibitors of Plk1 activity have been 
developed. In cancer cells, the silencing of Plk1 expression using RNA interference or 
small molecule inhibitors results in various biological effects, including G2/M 
accumulation, mitotic catastrophe, apoptosis, and senescence (48-50).  Knockdown of 
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Plk1 using siRNA in primary human cells reduces the rate of cell division but did not 
increase apoptosis significantly (51, 52).   
Small molecule inhibitors of Plk1 inhibitors have been developed as therapeutic 
strategies for cancer. These Plk1 inhibitors are ATP competitive inhibitors that bind to 
the ATP binding site of Plk1 and prevent its enzymatic activity. The Plk1 inhibitors 
currently most advanced in clinical development are: BI2536, BI6727 (volasertib), and 
GSK461364. All three are ATP-competitive kinase inhibitors.  BI2536 and volasertib 
(both from Boehringer Ingelheim) are dihydropteridinone derivatives. In cell culture 
assays, BI2536 inhibits the proliferation of a variety of human cancer cell lines with 
IC50 values ranging from 2 to 25 nM. Following treatment with BI2536, cancer cells are 
arrested in pro-metaphase, stain positive for phospho-histone H3 indicating chromatin 
condensation . These cells have also been reported to aberrant numbers of mitotic 
spindles with unfocused poles, and have misaligned chromosomes on the mitotic 
spindles . In addition to mitotic arrest, these treated cells undergo apoptosis as seen by 
poly-(ADP-ribose) polymerase (PARP) cleavage, flow cytometry and TUNEL assays 
(53).  
However the effects on cancer cell lines are not uniform and some lines are 
resistant to the effects of Plk1 inhibition or knock-down (48). Due to these varying 
responses to treatment options, it is important to establish biomarkers of response to 
different therapies. Currently, there are no established predictive biomarkers of 
response for Plk1 inhibitors. Some potential biomarkers include p53 and KRAS. Tumors 
with both p53 deficiency and high Plk1 expression may be more sensitive to Plk1 
inhibitors, although some controversial data exist (31). p53 deficient cells have been 
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reported to have decreased cell growth in comparison to p53 wild type cells after 
treatment with small-molecule inhibitors of Plk1 (54).    
On the other hand, in Plk1 expression may be essential for the proliferation of 
KRAS mutant cancers because .However, detailed studies investigating the effects of 
Plk1 inhibitors in KRAS mutant cancers have not been reported.  In stably oncogenic 
KRAS-G13D mutant colorectal cancer cells, cell death was increased by Plk1 depletion 
using shRNA or treatment with the Plk1 inhibitor, BI2536 (52). KRAS mutant cells 
treated with BI2536 accumulated in G2/M, suggesting that KRAS-mutant cells depend 
more on Plk1 for mitotic progression than cells with wild type KRAS, and that KRAS 
mutant tumors may respond well to drugs which inhibit Plk1.   
BI2536 has been studied in Phase I and II clinical trials; however, it has not 
shown sufficient levels of antitumor activity for further clinical development in solid 
tumors. In single agent clinical trials of BI2536 in refractory solid tumors, a fraction of 
patients respond: 14% urothelial (55),  4.2 % in NSCLC, 5% in advanced solid tumors 
(55, 56). This has been caused, in large part, to poor pharmacokinetic properties, and 
off target effects that result in the inhibition of Plk3, a tumor suppressor (57). In contrast, 
volasertib has advanced from clinical trials and recently has been given “breakthrough 
status” by the FDA after significant benefit was observed in treating acute myeloid 
leukemia in combination with cytarabine (58). The results of a Phase I clinical trial for 
GSK461364 have also been recently published (59).  
Non-ATP competitive Plk1 inhibitors have been in development, primarily 
targeting the polo box domain (60). The focus of these non-competitive inhibitors is on 
minimizing the binding of phosphopeptides to the PBD, thus preventing the 
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conformational change that opens up the kinase domain for further activation. These 
inhibitors have not been extensively studied to date. 
 
Plk1 inhibitors in NSCLC 
 Plk1 inhibitors have not been extensively studied in NSCLC. NSCLC patients 
with higher levels of Plk1 expression have worse prognosis (60). Studies in non-
selected, refractory NSCLC patients showed 4% of these patients had a significant 
benefit from Plk1 inhibitors (35). The three Plk1 inhibitors which are most relevant 
clinically are volasertib, GSK461364, and BI2536. Volasertib was found to have 
antitumor activity against H460 NSCLC cell line in vitro and in mice (61). GSK461364 
had antitumor activity against 2 of 3 NSCLC cell lines in mice (61). In 3 NSCLC cell 
lines, BI2536 led to prolonged spindle assembly checkpoint and subsequent mitotic 
catastrophe (62). BI2536 has been combined with pemetrexed in NSCLC and 2 of 33 
patients had a partial response (61). Additionally, siRNA targeting Plk1 led to cell cycle 
arrest and apoptosis of NSCLC cell line in vitro and decreased tumor growth in vivo 
(63). It has been shown that Plk1 inactivation has antitumor activity in a small subset of 
NSCLC cells. The observed effects of Plk1 inhibition in a subset NSCLC may be linked 
to the epithelial or mesenchymal phenotypes often observed in NSCLC cell lines (64). 
 
 
Epithelial to Mesenchymal Transition (EMT) 
EMT is a process which was first characterized in embryonic development (65). 
EMT allows an epithelial cell to lose its polarity, cell adhesion, and causes it to become 
migratory and invasive, hence, becoming a mesenchymal cell. A mesenchymal cell has 
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several properties, including that it is more mobile, invasive, and can evade 
programmed cell death (66).   
 
 
   
Figure 3. Epithelial to mesenchymal transition EMT is the transition of a polarized 
epithelial cell into a mobile mesenchymal cell. Several factors play a role in this 
transition. Reprinted by permission from AMERICAN SOCIETY FOR CLINICAL 
INVESTIGATION: Journal of Clinical Investigation, Kalluri R, Weinberg RA. The basics 
of epithelial-mesenchymal transition. The Journal of Clinical Investigation. 
2009;119(6):1420-8. 2009. (67) 
 
EMT and its reverse process, the mesenchymal to epithelial transition (MET) are very 
important in several developmental processes including gastrulation, neural crest 
formation, and myogenesis (68). It is also extremely important in wound healing, and 
plays a role in metastasis of cancer.  The loss of the protein E-cadherin is a crucial 
event of EMT (67). Several transcription factors including Snail and ZEB1 inhibit E-
cadherin by binding to its promoter and inhibiting its transcription. The miR-200 family of 
micro RNAs are known to directly target mRNA of repressors of E-cadherin, such as 
ZEB1 (69). Other transcription factors can repress tight-junction related proteins 
including claudins and desmosomes which also enhances EMT (67).  
Additionally, signaling pathways including TGF- β, FGF, EGF, HGF, Wnt and β-
catenin and Notch have been known to facilitate EMT transitions (70). RAS and MAPK 
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pathways have been shown to activate the transcription factors Snail and Slug (71). 
TGF-β is a significant inhibitor of epithelial cell proliferation and primary cell 
tumorigenesis. It can also serve as a positive regulator of tumor progression and 
metastasis (72). In vitro studies have demonstrated that TGF-β can induce an EMT in 
certain types of cancer cells by way of Smad-protein mediated signaling (73). Through 
ligand binding with the TGF- β receptors, Smad family proteins are activated and form a 
complex which translocates into the nucleus of cells to transcriptionally regulate target 
genes (74). This signaling can activate transcription factors which promote EMT. TGF- β 
signaling induces expression of micro RNAs which repress epithelial proteins. 
Additionally, TGF- β can induce pathways which are not related to Smad signaling 
which still contribute to EMT. These include activation of the PI3K-AKT pathway 
signaling, as well as regulation of Rho-GTPases which are involved in cell junction 
destruction (74). 
 
EMT and cancer 
EMT is known to play roles in both development and in cancer. The primary 
difference between the two is that in normal cells, these events are highly regulated, 
both spatially and temporally, where in cancer cells, such processes are not strictly 
regulated and can bypass certain events and checkpoints (75). During tumorigenesis 
(Figure 4), EMT helps cancer cells become more motile and invasive (67). The 
transformation to malignancy is associated with signaling pathways which promote 
EMT.  
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Figure 4. Epithelial to mesenchymal transition in cancer Cancer cells undergoing 
EMT have to go through several stages to invade and establish in a secondary site. 
Reprinted by permission from AMERICAN SOCIETY FOR CLINICAL INVESTIGATION: 
Journal of Clinical Investigation, Kalluri R, Weinberg RA. The basics of epithelial-
mesenchymal transition. The Journal of clinical investigation. 2009;119(6):1420-8. 2009. 
(67). 
 
 The growth of neoplastic cells after transformation is quite slow, and for the 
tumor to grow to a certain size, it needs to vascularize (76). Invasion of the stromal cells 
of the host is important for the tumor to replenish the nutrients and other factors needed 
to survive (76). Epithelial to mesenchymal transitions facilitate this process, as the 
primary cells are more invasive and motile and are able to break through the basement 
membrane and are able to enter the bloodstream (67). As the cells are able to enter the 
bloodstream, they are able to adhere to other cells, eventually escape, and establish a 
secondary tumor at a distant site. 
 
EMT and cell cycle 
Few studies have linked the important features of cancer, EMT and the cell 
cycle.   These reports suggest that upregulation of some Rho GTPases can increase 
the invasive capabilities of cancer cells. These Rho GTPases, known to have functions 
in deteriorating cell junctions and cytoskeletal changes, have been reported to 
downregulate cyclin A2, which binds to CDK2 and CDK1, important in S phase and 
G2/M phase progression, respectively (77). Additionally, TGF-β, a known inducer of 
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EMT is known to induce survivin, which stabilizes Aurora B. Aurora B is a kinase which 
plays an important role during the cell cycle by activating Plk1 (78).  
 
 
The link between EMT and Plk1 has not been explored and needs to be 
elucidated further in NSCLC. Based on gene and protein expression in NSCLC cell lines 
in our study, EMT related genes and proteins were significantly correlated with 
response to Plk1 inhibition. In this thesis, we examine the responses of NSCLC cell 
lines to Plk1 inhibition. We then proceed to look at the biological effects of Plk1 
inhibition on NSCLC cell lines. Finally, we assess the relationship of gene and protein 
expression to Plk1 inhibitor sensitivity to find predictive biomarkers of response to Plk1 
inhibition. 
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Chapter 2: Materials and Methods 
This chapter is based upon our submitted manuscript entitled “Epithelial-Mesenchymal 
Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell 
Lung Cancer” which is currently under review. 
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Antibodies and reagents 
The following antibodies were used: anti- Plk1 (Invitrogen); phosphorylated Myt1 
(Thr495) and Myt1 (Thermo Scientific); phosphorylated CDK1 (Tyr15), FOXM1, PARP, 
cleaved PARP, phosphorylated translational controlled tumor protein (TCTP) (Ser46), 
Cyclin B, E-cadherin, TCTP, vimentin, β-catenin, and ZEB1 (Cell Signaling Technology); 
and β-actin (Sigma). The Plk1 inhibitors BI2536, volasertib, and GSK461364 and P-
glycoprotein inhibitor PSC-833 were purchased from Selleck Chemicals (Houston, TX) 
and prepared as 10 mM stock solutions in dimethyl sulfoxide. We used predesigned 
sets of 4 independent siRNA sequences of the target genes PLK1 and CDH1 
(siGENOME SMARTpool, Dharmacon, Thermo Scientific, Pittsburgh PA). The human 
TGF-β1 was purchased from Cell Signaling Technology. 
 
Cell culture and characterization 
Sixty three human NSCLC cell lines were authenticated with DNA fingerprinting, 
routinely tested for Mycoplasma spp., and maintained as previously described (79). The 
cell line Cal-12T was purchased from DSMZ. The cell lines’ mutational profiles for 264 
genes (Supplemental Table 1) were obtained from the catalog COSMIC (version 67) 
and the Cancer Cell line Encyclopedia.  Baseline mRNA (48,804 probe sets) and 
protein (193 proteins and phosphoproteins) expression levels were determined using 
Illumina and reverse phase protein arrays, respectively, as previously described (80, 
81). 
 
 
 
40 
 
Cell viability assays 
Fifty NSCLC cell lines were incubated with dimethyl sulfoxide (vehicle control), BI2536, 
or volasertib for 120 h at nine distinct concentrations, with the maximum dose being the 
peak concentration of each drug in humans (Cmax): 1.6 µM for BI2536 and 1.2 µM for 
volasertib. Cell viability was measured using the MTT assay as previously described 
(82). For GSK461364, 63 NSCLC cell lines were incubated with dimethyl sulfoxide or 
GSK461364 for 72 h at seven distinct concentrations, with the maximum dose being the 
Cmax (1 µM). CellTiter-Glo luminescent cell viability assay (Promega) was performed per 
the manufacturer’s specifications. For both assays, six replicates were tested each 
concentration, and each test was completed at least twice on different days. 
For colony formation assays, cells were treated for 24 h with dimethyl sulfoxide or 
volasertib and then incubated in drug-free medium for 14 to 21 days. Plates were 
stained with crystal violet, and total colony area per well was estimated using ImageJ 
software as previously described (79, 83). 
 
 
Calculation of the drugs’ effects on viability 
IC50 and IC70 values were estimated from the best-fit dose-response model selected 
by calculating residual standard error using the R packages Dose Finding and drc 
(84).  For many cell lines, the dose-response curve plateaued at or near the IC50, so we 
used IC70 values to distinguish sensitive and resistant cell lines. Cell lines with IC70 
values greater than the Cmax were considered resistant; cell lines with IC70 values less 
or equal to the Cmax were classified as sensitive. 
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Statistical analysis 
IC50 and IC70 values were estimated from the best-fit dose-response model selected 
by calculating residual standard error using the R packages Dose Finding and drc (84).  
Gene expression data were available for 43 of the 50 cell lines treated with BI2536 and 
volasertib and 50 of the 63 lines treated with GSK461364. Forty-one cell lines had gene 
expression and drug sensitivity data for all 3 drugs. Reverse phase protein array 
(RPPA) data were obtained as previously described and available for 44 lines tested 
with BI2536 and volasertib and 45 lines tested with GSK461364 (80, 81).  For the cell 
lines that were consistently sensitive or resistant to all 3 drugs (universal group), gene 
expression data were available for 10 sensitive and 11 resistant lines, and protein 
expression data were available for 10 sensitive and 13 resistant lines. 
 
To compare gene and protein expression patterns between resistant and sensitive lines, 
two-sample t-tests were performed on a gene-by-gene or protein-by-protein basis. To 
adjust for multiple testing, we applied the beta-uniform mixture model to modelling P 
values in order to select an appropriate false discovery rate cutoff (85). For correlations 
between drug sensitivity and gene mutations, we performed Fisher exact test. 
Additionally, associations between drug sensitivity and epithelial-mesenchymal 
transition (EMT) scores (80) were evaluated using two-sample t-tests. 
 
To evaluate pre-established signatures for KRAS dependency (64) and chromosomal 
instability (86), we applied a two-way hierarchical clustering technique to the dataset in 
order to produce heat maps (80).  We tested correlation between the sensitivities of 
three drugs using the chi-square test.  For assessment of association between each 
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pair of drugs, we performed the Fisher exact test. All statistical analyses were 
performed using R software (87). 
 
Pathway analysis was performed with the Ingenuity Pathway Analysis tool 
(http://www.ingenuity.com/) using gene sets as described in the Results section.  
 
Cell cycle analysis and apoptosis assays 
For cell cycle analysis, cells were harvested, fixed, incorporated with 
bromodeoxyuridine (BrdU) and stained with 7-aminoactinomycin D (7AAD) (BrdU Flow 
kit; BD Biosciences). DNA content was analyzed with a cytofluorimeter, a fluorescence-
activated cell sorter (FACScan; Becton Dickinson), and the ModFit software program 
(Verity Software House) (79). To measure apoptosis, we used TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick end labeling) staining (APO-BrdU kit; BD 
Biosciences) and quantitated bromodeoxyuridine incorporation by fluorescence-
activated cell sorting (BrdU Flow kits; BD Biosciences) according to the manufacturers’ 
protocols. 
 
Western blotting  
For Western blots, sub-confluent cells were lysed on ice, and the lysates were 
centrifuged at 20,000g for 5 min at 4°C as described previously (79). Whole-cell lysates 
containing 30 to 50 μg of proteins were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, immunoblotted with the indicated primary 
antibodies, and detected with horseradish peroxidase-conjugated secondary antibody 
(Bio-Rad Laboratories) and an enhanced chemiluminescence reagent (Amersham 
Biosciences). 
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Transient Transfection 
Cultured cells were plated in six-well plates 24 hours prior to transfection. On the 
following day, cells were transfected RNA iMax. siRNA was mixed with the reagent in 
serum free media. Liposomal complexes were formed in the serum free media and 
incubated at the room temperature for five minutes. The mixture was then added to the 
indicated wells and incubated for the indicated time points.  
 
Inducible miR-200 Transfections 
A modified doxycycline-inducible pTRIPz-RFP vector expressing miR-200a, miR-200b, 
or both (miR-200ab) was generously provided by Dr. Gregory Goodall at the University 
of Adelaide. H157 NSCLC cells were transduced by Lipofectamine LTX or lentiviral 
delivery of  pTRIPz–miR-200, ZEB1B or a control vector.  Lentiviruses were produced 
by cotransfecting HEK-293 cells with 1.5 µg of the viral packaging vector psPAX2, 0.5 
µg of the viral envelope vector pMD2.G, and 2 µg of pTRIPz–miR-200 or the control 
vector using Lipofectamine LTX.  HEK-293 cell medium was changed 24 h after 
transfection, and the cells were incubated at 37oC for 48 h to allow for virus 
production.  After 48 h, HEK-293 media containing virus particles were transferred onto 
H157 NSCLC cell culture plates and incubated at 37oC for 48 h.  After transduction, 
fresh RPMI 1640 medium with 10% FBS was added to the H157 cell culture plates, and 
the cells were allowed to recover for 24 h. Cells were selected using 3 µg/mL 
puromycin, and 2 µg/mL doxycycline was used for induction of miR-200 and 
RFP.  Induced RFP expression was used to visually verify successfully infected 
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cells.  H1299 cells expressing miR-200 were sorted using flow cytometry for RFP 
positivity to obtain the transfected cell population. 
 
H1299 cells were transfected with 4 µg of pTRIPz–miR-200 or the control vector using 
Lipofectamine LTX.  After 24 h of transfection, cells were selected using 3 µg/mL 
puromycin in RPMI 1640 with 10% FBS.  Expression of miR-200 and RFP was induced 
with 2 µg/mL doxycycline.  H1299 cells expressing miR-200 were sorted using flow 
cytometry for RFP positivity to obtain the transfected cell population. 
 
Immunofluorescence Microscopy 
Cells were plated on MilliCell EZ-Slides (Millipore). After 24 hours, the cells were treated 
with vehicle or volasertib for the time points indicated. Following treatment, cells were 
rinsed with PBS, fixed with 4% paraformaldehyde. After washing, the samples were 
blocked in 1% BSA, and primary antibody was added. Slides were kept overnight in 
4°C. Afterwards, the cells were washed, and were incubated with the secondary 
antibody for one hour, protected from light. After washing, mounting media with DAPI 
was added along with coverslips. Slides were visualized using a fluorescence 
microscope. 
 
H&E staining 
Cells were plated on MilliCell EZ-Slides (Millipore). After 24 hours, the cells were treated 
with vehicle or volasertib for the time points indicated. Following treatment, the cells 
were washed with PBS, fixed with 4% paraformaldehyde. Then cells were stained with 
hematoxylin for one minute, washed with tap water for bluing. Following this, cells were 
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dehydrated with increasing concentrations of ethanol. Cells were then stained with 
eosin for one minute, and excess eosin was removed by ethanol washing. Following 
this, slides were air-dried and mounted with DPX. 
 
ELISA Plk1 activity assay 
A Plk1 ELISA assay from MBL Technologies was used to assess Plk1 activity after 
treatment with volasertib. Briefly, subconfluent cells were pre-treated with the inhibitor 
for the indicated time points, harvested, lysed, and used immediately afterward for the 
assay. The concentration of the protein was quantified using the Bradford method and 
added to the ELISA plate coated with the substrate. After incubation to bind the 
substrate, there was incubation with the kinase buffer, followed by incubation with the 
primary anti-phospho-threonine antibody. This was followed by incubation with the 
HRP-linked secondary antibody, which was then detected after incubation with HRP 
substrate, and the optical density was measured at a wavelength of 450nm.  
 
Doubling Time (DAPI) 
Cells were seeded in a 384 well plate at different densities ((125 cells/well, 250 
cells/well, 500 cells/well, 1000 cells/well and 2000 cells/well). After one day, the cells 
were fixed in 1% paraformaldehyde for 10 minutes. Following fixation, DAPI was added 
to the cells and cells were counted using an INCELL analyzer. This was repeated at 48, 
72, and 96 hour time points. The averages and standard deviations are calculated, and 
the doubling time was calculated using the following equation: 3*(LOG(2)/LOG(96h Std 
Dev. /48h Std Dev.)). 
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Kaplan Meier Plotter 
For Kaplan Meier analysis, we used Kaplan Meier Plot software analysis from 
www.kmplot.com (88). We used the latest 2015 version of the database generated from 
1926 lung cancer patients. In our analysis, we included adenocarcinomas and 
squamous carcinomas, with stage III/IV disease; we did not restrict based on gender, 
and smoking status.  
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Chapter 3. Results 
This chapter is based upon our submitted manuscript entitled “Epithelial-Mesenchymal 
Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell 
Lung Cancer” which is currently under review. 
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Plk1 overexpression correlates with poor survival in lung patients 
To enforce Plk1 as a target for further study, we determined the correlation of Plk1 
mRNA expression and progression free survival in 2435 lung cancer patients.  Using 
the Kaplan Meier Plotter, we utilized microarray data which had been published from the 
caArray project, Gene Expression Omnibus (GEO), and The Cancer Genome Atlas 
(TCGA) (88).  Patients were not differentiated based on smoking history or gender. 
There was a significant relationship (p = 4.8e-15) between high Plk1 mRNA expression 
and lower survival (Fig. 5). To determine the cutoff for the gene, the percentile of 
expression between the lower and upper quartiles were computed, and the best 
predictive threshold was used as the cutoff through univariate Cox regression (88). 
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Figure 5. High Plk1 mRNA expression correlates with lower progression free 
survival in lung cancer patient samples. Kaplan Meier curve showing the Plk1 mRNA 
expression and progression free survival generated from www.kmplot.com. (n = 2435 
patients).  
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NSCLC cell lines have diverse sensitivities to Plk1 inhibitors 
The Genomics of Drug Sensitivity in Cancer contains drug sensitivity data on 14 
NSCLC cell lines treated with 2 Plk1 inhibitors (Fig.6a) (89).  To enhance future clinical 
translation, we used the three most clinically advanced Plk1 inhibitors, BI2536, BI6727 
(Volasertib), and GSK461364. We tested 50 NSCLC cell lines for sensitivity to BI2536 
(Cmax 1.6 μM) and volasertib (Cmax 1.2 μM) using MTT viability assays. To validate 
our findings, we also separately tested 63 NSCLC lines with GSK461364 (Cmax 1.0 
μM) using CellTiter Glo assays (GSK461364 was tested by Drs. Uma Giri and Shaohua 
Peng, in collaboration with Dr. John Heymach’s lab). Dose response curves were 
generated for these data and distinct groups were observed (Fig. 6b). Cell lines’ 
sensitivity to the drugs varied widely.  In many cell lines, the dose response curves 
plateaued near the IC50. To better distinguish the sensitive and resistant cell lines, we 
used the IC70 values. Those cell lines which had IC70 values which were lower than 
the Cmax for the drug were considered sensitive and those which did not reach the 
IC70 value prior to the Cmax were considered resistant which resulted in a dichotomous 
population.  
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Figure 6.  NSCLC cell lines have diverse sensitivities to Plk1 inhibition.  (A) Drug 
sensitivity for two Plk1 inhibitors in 14 NSCLC cell lines was obtained from the GDSC 
online database (left).  Each data point indicates the IC75 values for one individual cell 
line.  NSCLC cell lines were treated with BI2536, volasertib, or GSK461364 for 72-120 
h, and viability was estimated using MTT or CellTiter-Glo assay.  Each data point 
indicates the IC70 for one individual cell line. The horizontal blue line on each chart 
represents the Cmax value for each drug, which was used as the cutoff for sensitivity.  
(B) Replicate data were graphed for each concentration, and the best dose-response 
model was selected by the residual standard error (RSE) method (84). The horizontal 
blue line on each dose response curve represents the IC70. The GSK461364 
compound was screened by Drs. Uma Giri and Shaohua Peng in collaboration with Dr. 
John Heymach’s laboratory. Dose response curves were generated in collaboration with 
the Bioinformatics Department, including Drs. Pan Tong, Suk-Young Yoo, and Jing 
Wang. 
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We then examined the correlation between the sensitivities drug to drug. 
Sensitivities to the three drugs were correlated at a p-value of 1.4e-06 (chi-square test). 
When drug sensitivities were compared pair-wise by the Fisher exact test, the 
correlation between BI2536 and volasertib (p = 1.1e-06), was stronger than that the 
correlation between GSK461364 and volasertib (p = 0.186) or between GSK461364 and 
BI2536 (p = 0.020).  This result was expected given these drugs’ structural and 
chemical similarities.  To ensure that the observed sensitivity differences were not due 
to technical differences between the MTT and CellTiter-Glo viability assays, we tested 
the universal lines for sensitivity to all three drugs using identical conditions.  Although 
the IC70 values were not absolutely identical between the two assays, all the universal 
cell lines remained in the same category (sensitive or resistant) regardless of the assay 
used (Table 2). 
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Table 2. MTT and CellTiter-Glo assays confirmed universal sensitive and 
universal resistant cell lines to three Plk1 inhibitors. After screening all cell lines we 
assayed the cell lines which were either sensitive to all three inhibitors (universally 
sensitive) or resistant to all three inhibitors (universally resistant) using both MTT and 
Cell TiterGlo assays. The IC70 values obtained are shown above. IC70 values were 
generated with the help of the Bioinformatics Department, including Drs. Pan Tong, 
Suk-Young Yoo, and Jing Wang. 
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BI2536, volasertib, and GSK461364 inhibit Plk1 targets in NSCLC cell lines 
To determine if BI2536, volasertib, and GSK461364 are indeed inhibiting Plk1 in 
the NSCLC cell lines, we used two universally sensitive cell lines, H1792 and Calu-6, 
and two universally resistant cell lines, H322 and H358, to study the effects of Plk1 
inhibition on known Plk1 targets. We examined the phosphorylation of Myt1 kinase at 
the inhibitory phosphorylation site of Thr495 for H1792 and H322 and phosphorylation  
of TCTP at Ser46 for all four cell lines, which are both known phosphorylation targets of 
Plk1 at different concentrations and time points. We examined the dose dependent 
response to determine the relevant dose needed to inhibit Plk1 in the cell lines (Fig. 7a), 
which we determined to be 50nM. We were able to see target inhibition persist up to 
120 hours, which mirrored the maximum time interval we exposed the cell lines to the 
drugs in the viability assays (Fig. 7b). As we expected, inhibition of Plk1 led to a 
decrease in phosphorylation of Myt1 in the NSCLC cell lines. We additionally observed 
that although TCTP phosphorylation after treatment, the decrease was much lower in 
the two resistant lines tested. We observed an increase in the levels of phospho-CDK1 
at Tyr15, indicating an inactive CDK1 after Plk1 inhibition using volasertib. Additionally, 
we were able to see stabilization of levels of cyclin B after Plk1 inhibition (Fig 7c).  
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Figure 7. Inhibition of Plk1 substrates after treatment with Plk1 inhibitors. NSCLC 
cell lines were incubated with dimethyl sulfoxide (vehicle control), BI2536, volasertib, or 
GSK461364 using the indicated concentrations for 2 h (A, B) or at 50 nM for the 
indicated periods (in hours) (D).  Cells were then lysed and subjected to Western 
blotting (A-D) with the indicated primary antibodies and (B) p-TCTP band density was 
quantitated. 
 
 
We noticed in the dose response western blots that there was incomplete target 
inhibition at higher doses, in regards to GSK461364. To test whether the drug was 
being actively pumped out by the cells, we also examined ATP binding cassette (ABC) 
protein expression that has been reported to be possible resistance mechanism for Plk1 
H1792 H322 
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inhibition (90). We observed that GSK461364 induced ABCC1 and ABCG2 expression 
at high concentrations (Fig. 8).  
 
Figure 8. Plk1 inhibition with GSK461364 led to increase in ABCB1 and ABCC1 
protein expression. Cells were incubated for 4 hours with 50nM GSK461364, lysed, 
and protein expression was analyzed through Western blot.  
 
 
 
Plk1 inhibition leads to lower Plk1 kinase activity in NSCLC cell lines 
To more directly test if Plk1 inhibitors were inhibiting Plk1 function, we assayed 
for Plk1 enzyme activity using an ELISA based assay that measures the 
phosphorylation of protein-X, a substrate of Plk1.  Plk1 activity was decreased up to 
80% with concentrations of 50 nM and 1 µM volasertib in extracted cell lysates to which 
inhibitor was added directly to the lysates (Fig 9a). NSCLC cell lines were incubated 
with 50nM volasertib for 24 and 48h time points. In intact cells, we observe a lower 
inhibition efficiency at short time points, and incomplete inhibition in resistant cell lines 
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(Fig. 9b). However, in experiments in which volasertib was added to the intact cells, 
volasertib was not added to the lysates incubated with the Plk1 substrate. 
A 
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Figure 9. Plk1 activity assay demonstrates inhibition of Plk1 kinase activity in 2h 
treated lysed cell extracts, and at 24 and 48h time points in pretreated cells. Plk1 
activity was assayed using an ELISA kit. Cells were either treated after lysis for four 
hours (A) or after treatment (B) with volasertib for the indicated time points. (C is vehicle 
control, T is treated with 50nM volasertib).  Asterisks represent significant differences (p 
< 0.05) for the treated samples compared to the controls. 
 
 
Plk1 inhibition leads to inhibition of colony formation in sensitive cell lines 
In the cell line screening, the cells were incubated for the complete time period 
with the drug. To measure if the effects of Plk1 inhibition in NSCLC cell lines were 
irreversible, we incubated two sensitive and two resistant NSCLC cell lines with 50 nM 
volasertib for 24 hours and measured colony formation 14-21 days later. Mirroring our 
results from the viability assays, the sensitive cell lines H1792 and Calu-6 had 
irreversible cell growth and inhibition of colony formation compared to the resistant cell 
lines H322 and H358 (Fig. 10a). As another marker for cell proliferation, we also looked 
at the effects of Plk1 inhibition on average colony size. Similarly to what is observed in 
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the total area, the average colony area decreases in sensitive and resistant NSCLC cell 
lines. Sensitive NSCLC cell lines have significantly greater reduction of average colony 
area at low concentrations (Fig 10b). 
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Figure 10. Sensitive cell lines show greater colony formation inhibition compared 
to resistant cell lines after 24h pulse treatment of volasertib. After 24h pulse 
treatment, there was a reduction in the cell colonies growing in the assay wells (given 
here as colony area in A) in the sensitive cell lines. As an additional measure of colony 
growth, average colony area was quantitated (B) for a sensitive cell line (Calu-6) and a 
resistant cell line (H322). There was significant (p < 0.05) decrease in average colony 
size compared to controls for Calu-6 at lower concentrations of the inhibitor compared 
to H322. (C) A representative scanned image of a sensitive cell line and a resistant cell 
line. *, P < 0.05 compared to control or as indicated. 
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Plk1 inhibition increases cells with 4N DNA content in NSCLC cell lines 
The effect of Plk1 inhibition in the cell cycle has been widely reported and known 
to cause prometaphase arrest (31, 53, 61, 91). We observed an accumulation of cells 
with 4N DNA content as well as an increase in cells with greater than 4N DNA content 
(Fig.11a-b). Additionally, there was a significantly increased sub G0 population of cells 
in the sensitive cell lines compared to the resistant cell lines. To confirm the finding of 
more polyploid cells after treatment, we used DAPI staining using immunofluorescence 
to locate multiple nuclei within single cells (Fig. 12a). Similar results were seen using 
brightfield microscopy after H&E staining (12b). In addition, we observed increased 
nuclear chromatin condensation in the sensitive cells after treatment with volasertib 
(12b), a marker of apoptosis (92). We found that there was an increase in polyploid cells 
post treatment with Plk1 inhibitor volasertib in resistant NSCLC cell lines.  
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Figure 11. Plk1 inhibition causes an accumulation of cells with 4N DNA content in 
sensitive and resistant cell lines. After Plk1 inhibition, there was an accumulation of 
cells with 4N DNA content after 24 and 48 hours for all cell lines. Sensitive cells had an 
increased sub-G0 population after treatment, and resistant cells had increased number 
of cells with >4N DNA content (A). A representative profile with gating is given for the 
resistant cell line H358 and sensitive cell line Calu-6 (B).  
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Figure 12. Plk1 inhibition increases the number of polyploid cells in resistant 
NSCLC cell lines. The cells were visualized using immunofluorescence microscopy (A) 
and brightfield microscopy (B) after treatment and staining. After quantitation (C), we 
observed an increase in the number of cells with more than one nucleus in the resistant 
cell line.  
 
 
Plk1 inhibition leads to apoptosis in NSCLC cell lines 
We also measured cell apoptosis in the two sensitive and two resistant lines. 
From the TUNEL assay, we were able to see that the sensitive NSCLC cell lines H1792 
and Calu-6 underwent significantly more apoptosis after 72 hour incubation with 
volasertib (Fig 13a). In comparison, the resistant H358 and H322 cell lines underwent 
less apoptosis compared to the sensitive cell lines. The results were validated using 
another marker of apoptosis, western blotting for cleaved PARP. Here we found an 
increase in cleaved PARP after treatment to Plk1 inhibitor volasertib in the two sensitive 
cell lines (Fig. 13b-c). 
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Figure 13. Plk1 inhibition causes significant apoptosis in sensitive cell lines but 
not resistant cell lines. After 72h treatment with volasertib, sensitive cell lines 
underwent significantly more TUNEL staining (A) and PARP cleavage (B) compared to 
resistant cell lines (p<0.05). (C) Cleaved PARP bands were quantified using 
densitometry and adjusted for loading with β-actin. *, P < 0.05 compared to control or as 
indicated. 
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Plk1 knockdown leads to cell cycle arrest and increased apoptosis in NSCLC cell 
lines 
To address the question of specificity of the inhibitors, we used Plk1 specific 
siRNA to knockdown Plk1 and study the effects on the cell cycle. We found that Plk1 
knockdown after 24 and 48 hours caused an accumulation of cells with 4N DNA content 
in the NSCLC cell lines, as well as an increased sub G0 population in sensitive cell lines 
(Fig. 14). Additionally, we observed that there was an increase in the number of cells 
undergoing apoptosis after 72 hours of the Plk1 knockdown. PARP cleavage and 
TUNEL positive cells was also increased in sensitive cell lines compared to the resistant 
cells tested after Plk1 knockdown (Fig. 15). 
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Figure 14. Plk1 knockdown using siRNA causes an increase in 4N cells. We 
observed an increase in sub-G0 cells in the sensitive cells while we observed an 
increase in polyploid cells in the resistant cells after Plk1 knockdown (A). Gated cell 
cycle profiles are given for a sensitive cell line Calu-6 and resistant cell line H322 after 
knockdown (B). 
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Figure 15. Plk1 knockdown causes  significant apoptosis in NSCLC cell lines. 
Plk1 knockdown causes an increase in TUNEL positive cells (A) and cleaved PARP (B) 
in sensitive NSCLC cell lines. (C) Cleaved PARP bands were quantified using 
densitometry and adjusted for loading with β-actin. *, P < 0.05 compared to control or as 
indicated. 
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Doubling time does not correlate with Plk1 inhibition sensitivity 
Theoretically, cells which cycle faster should go through G2 of the cell cycle more often 
and may be vulnerable to inhibition of Plk1. We studied if cell doubling time plays a role 
sensitivity because Plk1 affects the cell cycles and cells that divide faster will go through 
the cell cycle more times than slower growing cells during the assays. These cells with 
shorter doubling time would therefore be in G2 for an increased time period, causing 
them to be more vulnerable to Plk1 inhibition. We measured the doubling time of 9 (5 
resistant, 4 sensitive) NSCLC cell lines. Using a two-sample t-test, there was no 
significant difference between the average doubling time and IC70 for the three Plk1 
inhibitors tested (Fig. 16). 
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Figure 16. Doubling time did not correlate with sensitivity to Plk1 inhibition. 
Doubling time was measured based on growth curve assays done by Dr. Uma Giri from 
Dr. John Heymach’s laboratory. Cell lines were grouped based on the definition of 
sensitive and resistant from the screening. There was no significant difference (p > 
0.05) between the sensitive cell lines and resistant cell lines for each of the inhibitors 
tested. 
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NSCLC cell lines with RAS mutations are more sensitive to Plk1 inhibition than 
those with wild-type RAS 
As KRAS mutations had been implicated with sensitivity to Plk1 inactivation (52, 
64), we examined the correlation between gene mutations for 264 genes that are 
commonly associated with cancer and drug sensitivity for all cell lines treated with 
BI2536 and volasertib and for 63 cell lines treated with GSK461364.  To be able to 
statistically analyze the RAS mutant cell lines, we grouped together the KRAS and 
NRAS mutant lines so as to have a larger sample size. More NSCLC cell lines with RAS 
mutations were sensitive to Plk1 inhibition than those with wild-type RAS (Table 3). No 
mutation other than RAS correlated with sensitivity for more than one drug.  We 
examined co-occurrence of other mutations within the RAS mutant population because 
co-mutations may define subgroups with distinct clinical outcomes and drug 
sensitivities. We did not find any statistical correlation between Plk1 inhibitor sensitivity 
and the presence of LKB or TP53 mutations within RAS mutant tumors possibly 
because the numbers of cell lines within these subgroups was small.  
To further characterize the KRAS mutants, we applied an established KRAS 
dependency signature to KRAS mutant NSCLC cell lines (64).  KRAS-dependent 
NSCLC cell lines, defined as those that undergo apoptosis when KRAS is knocked 
down, demonstrated classical epithelial morphology, whereas KRAS-independent cells 
demonstrated a mesenchymal phenotype (64).  In an unsupervised analysis, KRAS-
independent cell lines clustered in the sensitive group for GSK461364 (p of 0.0052) but 
not for the other 3 groups (Fig. 17). 
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Gene and 
drug 
sensitivity 
No. of cell lines P  
(Fisher 
test) 
Mutant Wild type 
Resistant Sensitive Resistant Sensitive 
RAS      
Universal 5 (38%) 8 (62%) 9 (81%) 2 (19%) 0.04718  
BI2536 9 (35%) 17 (65%) 18 (75%) 6 (25%) 0.005402  
Volasertib 8 (31%) 18 (69%) 16 (67%) 8 (33%) 0.02248  
GSK461364 20 (63%) 12 (37%) 22 (71%) 9 (29%) 0.595 
 
Table 3. Cell lines with RAS mutations are more sensitive to Plk1 inhibition for 
BI2536 and volasertib, but not GSK461364. Cell lines with KRAS and NRAS 
mutations were grouped together to form a RAS mutant group. Cells with RAS 
mutations (KRAS or NRAS) were more sensitive (p<0.05) to Plk1 inhibition for BI2536 
and volasertib, but not GSK461364 (p>0.05).  
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Figure 17. Genes associated with KRAS dependency correlate with sensitivity to 
GSK461364. In an unsupervised analysis, KRAS independent cells clustered in the 
sensitive region (p = 0.0052) for GSK461364, but not for the other two inhibitors or the 
universal lines. We generated heatmaps using an established KRAS-dependency 
signature (64) in KRAS mutant NSCLC cell lines with the help of the Bioinformatics 
department (Drs. Suk-Young Yoo, Pan Tong, Jing Wang) (64).  Out of the 44 genes in 
the signature, we identified 31 genes with 42 probes in our gene expression data. The 
following numbers of cell lines were identified with expression data available for the 
genes of interest: for BI2536, 7 sensitive and 11 resistant cell lines; for volasertib, 11 
sensitive and 5 resistant cell lines; for GSK461364, 12 sensitive and 17 resistant cell 
lines; and for all three drugs, 9 sensitive and 4 resistant cell lines.  
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TP53 mutation and the expression of ABC transporters do not correlate with 
response to Plk1 inhibition in NSCLC cell lines.  
In order to validate candidate biomarkers of response according to the available 
literature, we tested correlation of TP53 mutational status (Fisher exact test), and gene 
expression of ABC transporters ABCB1 and ABCG2 (two-sample t test) with sensitivity 
to the three Plk1 inhibitors (Fig 18). No statistically significant correlation was found 
(P>0.05). 
 
 
Figure 18. Expression of ABC transporter proteins did not correlate with 
sensitivity to Plk1 inhibitors. The gene expression of ABC transporter proteins 
ABCB1 and ABCG2 did not correlate with sensitivity to the Plk1 inhibitors tested 
(p>0.05). 
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Mesenchymal NSCLC cell lines are more sensitive to Plk1 inhibition than 
epithelial NSCLC cell lines 
To determine why NSCLC cell lines had diverse sensitivities to Plk1 inhibition, we 
examined the relationship between drug sensitivity and basal gene/protein expression in 
four groups of cell lines: BI2536-sensitive/resistant, volasertib-sensitive/resistant, 
GSK461364-sensitive/resistant, and the universal cell lines.  We found that the 
expression levels of several genes and proteins correlated with sensitivity to the Plk1 
inhibitors (Fig. 19).  
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Figure 19. Baseline mRNA and protein expression correlates with sensitivity and 
resistance in universal cell lines. Shown are heatmaps of baseline gene expression 
after supervised clustering of the universal cell lines at FDR of 0.2 (n = 91 genes) and 
baseline protein expression after supervised clustering of the universal cell lines at FDR 
of 0.3 (n = 8 proteins). 
 
 
 
We hypothesized that genes that were found in all four groups and that had the 
biggest differences in expression between resistant and sensitive cell lines would be the 
most likely to be involved in sensitivity specifically to Plk1 inhibition rather than to be 
involved in off-target drug effects.  After correction for multiple comparisons, no gene 
expression levels correlated with sensitivity to BI2536 or volasertib.  We discovered that 
the expression levels of several genes and proteins correlated with drug sensitivity 
(Table 4, 5). 
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Probe ID 
Gene 
Symbol Gene name Function 
Mean 
Expression 
(R/S)1,2 
ILMN_1770940 CDH1 E-cadherin adhesion, epithelial marker 59.95 
ILMN_2412475 PRR5 proline rich 5 
tumor supressor gene, 
component of mTORC2 
signalling 58.17 
ILMN_1791826 RAB25 
member RAS 
oncogene family 
membrane trafficking, 
member of the RAS family 33.86 
ILMN_1782389 LAD1 ladinin 1 
anchorin filament, epithelial 
marker 33.72 
ILMN_2143685 CLDN7 claudin 7 
tight junction, epithelial 
marker 27.42 
ILMN_1752935 TMEM30B 
transmembrane 
protein 30B phospholipid translocator 25.59 
ILMN_2160210 EPCAM 
epithelial cell 
adhesion 
molecule 
adhesion molecule, 
epithelial marker 24.24 
ILMN_1680110 
C10orf116 
(ADIRF) 
adipogenesis 
regulatory factor 
function unknown, 
overexpressed in 
cancers/platin resistance 23.40 
ILMN_1752932 MPZL2 
myelin protein 
zero-like 2 
cell adhesion/epithelial 
marker 21.60 
ILMN_1796461 PRSS8 
protease, serine, 
8 
membrane-anchored 
serine proteases/epithelial 
development 21.46 
ILMN_1655261 ERP27 
endoplasmic 
reticulum protein 
27 
endoplasmic reticulum 
protein   18.81 
ILMN_1699887 ST14 
suppression of 
tumorigenicity 14 
epithelial-derived, integral 
membrane serine protease 
(HGF family) 12.61 
ILMN_1710644 MARVELD3 
MARVEL domain 
containing 3 tight junction 11.71 
ILMN_1780255 KLK6 
kallikrein-related 
peptidase 6 
proliferation/epithelial 
marker 11.36 
ILMN_1664265 EPHA1 EPH receptor A1 angiogenesis/invasion 10.11 
ILMN_1801697 
C19orf46 
(SYNE4) 
spectrin repeat 
containing, 
nuclear envelope 
family member 4 
involved in changes in 
cellular organization 9.93 
ILMN_1685709 TMEM125 
transmembrane 
protein 125 
transmembrane protein, 
function unknown 9.73 
ILMN_1746801 CGN cingulin tight junction 8.97 
ILMN_1688154 MST1R 
macrophage 
stimulating 1 
receptor (c-met-
related tyrosine cell migration 7.55 
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kinase) 
ILMN_1751346 ERBB3 
v-erb-b2 avian 
erythroblastic 
leukemia viral 
oncogene 
homolog 3 
membrane protein from 
EGF receptor family - 
oncogenic 7.53 
ILMN_1769201 ELF3 E74-like factor 3 
epithelial-specific 
transcription factor, 
epithelial marker 7.44 
ILMN_2132599 ANKRD22 
ankyrin repeat 
domain 22 epithelial marker 7.01 
ILMN_2064150 PRRG2 
proline rich Gla 
(G-
carboxyglutamic 
acid) 2 
Hippo tumor suppressor 
pathway 6.85 
ILMN_1723092 CRB3 
crumbs family 
member 3 tight junction 6.78 
ILMN_2111932 
SERINC2 
(TDE2) 
serine 
incorporator 2 
byossinthesis of membrane 
lipids, overexpressed in 
lung cancer 6.23 
ILMN_2060145 GRHL2 
grainyhead-like 2 
(Drosophila) 
regulates ERBB3, involved 
in EMT 6.13 
ILMN_1713952 C1orf106 
chromosome 1 
open reading 
frame 106 function unknown 5.67 
ILMN_1676322 
C1orf172 
(KDF1) 
keratinocyte 
differentiation 
factor 1 proliferation/differentiation 5.61 
ILMN_2405254 GRB7 
growth factor 
receptor-bound 
protein 7 cell migration 5.49 
ILMN_1717052 STARD10 
StAR-related lipid 
transfer (START) 
domain containing 
10 
phospholipid transfer 
protein 4.97 
ILMN_2352131 ERBB2 
v-erb-b2 avian 
erythroblastic 
leukemia viral 
oncogene 
homolog 2 
EGF receptor family - 
oncogenic/cell proliferation 4.40 
ILMN_2043079 ILDR1 
immunoglobulin-
like domain 
containing 
receptor 1 
involved in cancer 
development/progression 4.36 
ILMN_2050790 C11orf52 
chromosome 11 
open reading 
frame 52 function unknown 4.24 
ILMN_1724946 
SPINT1 
(HAI1) 
serine peptidase 
inhibitor type 1 
regulates membrane 
anchored serine proteases 
(HGF family) 3.94 
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ILMN_1734596 TC2N 
tandem C2 
domains, nuclear 
involved in vesicular 
traffecking 3.87 
ILMN_1692398 CNTNAP1 
contactin 
associated protein 
1 involved in Rho signalling 0.25 
ILMN_2049536 TRPV2 
transient receptor 
potential cation 
channel, 
subfamily V, 
member 2 cell migration/invasion 0.16 
ILMN_1790778 PNMA2 
paraneoplastic Ma 
antigen 2 paraneoplastic antigen 0.13 
ILMN_2058251 VIM vimentin 
intermediate 
filament/cytoskeleton, 
mesenchymal marker 0.05 
 
Table 4.  Probe sets with expression that correlated with response to all three 
drugs. 
 
1Fold change in mean gene expression for resistant (R) / sensitive (S) cell lines.  
2P <0.015 for all values. 
 
 
 
At the protein level, E-cadherin and β-catenin were consistently expressed at higher 
levels in the resistant lines, and DNA-dependent protein kinase catalytic subunit and 
thymidylate synthase were consistently overexpressed in the sensitive lines as seen in 
Table 5. 
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Sensitivity 
 
Protein 
Mean 
expression 
(R/S) P  
Universal 
FDR = 0.1 E-cadherin 6.65 8.90E-07 
  β-catenin 4.27 5.29E-05 
FDR = 0.2 ATM 0.44 0.0041 
  TAZ 0.84 0.0043 
FDR = 0.3 Thymidylate synthase 0.62 0.0088 
  DNA-PKcs 0.54 0.0104 
  BCl2 0.62 0.0163 
  MCAM 0.80 0.0179 
GSK461364 
FDR = 0.2 E-cadherin 3.78 0.0001 
  β-catenin 2.46 0.0010 
FDR = 0.3 Thymidylate synthase 0.68 0.0041 
  Rab25 1.23 0.0042 
  P70s6k 1.35 0.0045 
  MACC1 1.62 0.0064 
BI2536 FDR = 0.1 E-cadherin 3.40 0.0008 
FDR = 0.2 DNA-PKcs 0.61 0.0040 
Table 5.  Proteins with expression that correlated with drug sensitivity 
R, resistant.  S, sensitive.  FDR, false discovery rate. PKcs, protein kinase catalytic 
subunit. 
  
As an exploratory analysis, we tested probe sets with at least a 2-fold difference 
in mean gene expression between sensitive and resistant lines and a corresponding P 
value of less than 0.05 for this difference.  We performed pathway analysis of lines with 
genes whose expression correlated with sensitivity to the universal lines. Tight-junction, 
ErbB, and Rho signaling pathways were significantly altered in multiple gene sets 
(Table 6). 
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Ingenuity canonical 
pathways P Genes 
Universal 
Tight junction 
signaling 3.5E-05 
F11R, JAM3, CGN, ARHGEF2, CLDN7, 
TNFRSF11B 
FDR  
< 0.2 RhoA signaling 0.001 
EPHA1, RTKN, BAIAP2, ARHGAP8/PRR5-
ARHGAP8 
 
Signaling by Rho 
family GTPases 0.002 MAP3K12, CDH1, RHOQ, BAIAP2, ARHGEF2 
 
RhoGDI signaling 0.004 
CDH1, RHOQ, ARHGEF2, ARHGAP8/PRR5-
ARHGAP8 
 
IL-15 production 0.004 PTK6, MST1R 
 
Production of  nitric 
oxide and reactive 
oxygen species in 
macrophages 0.004 MAP3K12,PTPN6,RHOQ,TNFRSF11B 
 
Leukocyte 
extravasation 
signaling 0.006 
F11R,JAM3,CLDN7,ARHGAP8/PRR5-
ARHGAP8 
 
Diphthamide 
biosynthesis 0.011 DPH5 
 
Epithelial adherens 
junction signaling 0.017 EPN3,CDH1,BAIAP2 
 
Actin nucleation by 
ARP-WASP 
complex 0.018 RHOQ,BAIAP2 
 
Acute phase response 
signaling 0.025 CRABP2,TAB,TNFRSF11B 
 
Granulocyte adhesion 
and diapedesis 0.028 JAM3,CLDN7,TNFRSF11B 
 
STAT3 Pathway 0.030 MAP3K12,PTPN6 
 
Molecular 
Mechanisms of 
Cancer 0.047 CDH1,RHOQ,ARHGEF2,TAB 
 
SAPK/JNK Signaling 0.048 MAP3K12,TAB 
 
PPAR Signaling 0.048 TAB,TNFRSF11B 
Table 6. Pathway analysis of genes that correlated with Plk1 inhibitor sensitivity 
in universal lines. Pathway analysis was performed using IPA from 
www.ingenuity.com.  
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Based on the differential expression of E-cadherin at mRNA and protein level 
(Fig. 20a-b) and several genes involved in EMT as well as our observations that NSCLC 
cells with a mesenchymal morphology were more sensitive to Plk1 inhibition than 
epithelial cells, we hypothesized that mesenchymal NSCLC cells are more sensitive to 
Plk1 inhibition.  We applied a 76-gene EMT signature score developed by our 
department and the bioinformatics department and which had been validated in multiple 
datasets to distinguish sensitive and resistant cell lines (80). EMT scores correlated 
significantly with sensitivity to Plk1 inhibition in cell lines sensitive to any one of the 
three drugs and particularly in universal lines (Fig. 20c). Cell lines with higher EMT 
scores (mesenchymal) were more sensitive to Plk1 inhibitors.  Protein expression as 
seen by Western blot also confirmed these correlations in the cell lines (Figure 20d). 
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Figure 20. Mesenchymal phenotype correlates with sensitivity to Plk1 inhibition 
while epithelial phenotype correlates with resistance. E-cadherin gene and protein 
expression is significantly correlated with resistance to Plk1 inhibition. Cell lines with 
higher EMT scores are also more sensitive to Plk1 inhibition. Expression boxplots were 
created with the help of the Bioinformatics department: Drs. Suk Young Yoo, Pan Tong, 
Jing Wang.  
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As Plk1 inhibitor sensitivity correlated significantly to E-cadherin expression, we 
examined the effect of knocking down E-cadherin on volasertib sensitivity.   
Manipulation of E-cadherin alone was not sufficient to change the biological effects of 
Plk1 inhibition (Fig. 20). 
 
Figure 21. E-cadherin knockdown did not sensitize resistant NSCLC cell lines to 
Plk1 inhibition. E-cadherin knock down does not affect NSCLC cell lines’ sensitivity to 
PLK1 inhibition.  Two epithelial NSCLC cell lines were transfected with siRNA to E-
cadherin and then incubated with volasertib 48 h later.  The knock down of E-cadherin 
did not affect cell cycle (left panel), cell number as measured by MTT (right panel) or 
apoptosis as measured by TUNEL (bottom panel). *, P < 0.05 compared to control or as 
indicated. 
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Induction of epithelial or mesenchymal phenotype affects sensitivity to Plk 
inhibition in NSCLC cell lines  
To determine if the correlation between EMT scores and drug sensitivity was 
biologically significant, we manipulated NSCLC cells and found that Plk1 inhibition led 
primarily to apoptosis in mesenchymal cells and cell cycle arrest in epithelial cells.  We 
transfected NSCLC cell lines with miR-200b and miR-200ab, which have been shown to 
induce an epithelial protein expression pattern and phenotype (93).  In the H1299 and 
H157 cell lines, miR-200b or miR-200ab, respectively, resulted in an increased 
expression of E-cadherin and a decreased expression of vimentin.  Concurring with the 
finding that the epithelial NSCLC lines are more resistant, the induction of an epithelial 
phenotype increased the cell lines’ resistance to volasertib, with IC70 values increasing 
from 374 nM to >1200 nM in H157 cells and from 321 nM to >1200 nM in H1299 cells 
(Fig. 21a). However, the quantity of TUNEL-positive cells did not significantly change 
between the uninduced cells and induced cells treated with volasertib. The induction of 
a mesenchymal phenotype using ZEB1 overexpression (Fig. 21b) increased the cell 
line’s sensitivity to volasertib, with IC70 values decreasing from >1200 nM to 130 nM. 
The quantity of TUNEL-positive cells did not significantly change between the control 
and ZEB1 cells after treatment with volasertib. TGF-β (Fig. 21c) induced a 
mesenchymal phenotype and led to an increase in sensitivity to volasertib, with cell 
viability decreasing by over 40%, although the IC70 values could not be detected. 
Additionally, TGF- β treated cells underwent significantly more (p < 0.05) apoptosis in 
terms of TUNEL stained cells compared to the parental cells.   
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Figure 22. Induction of EMT sensitizes NSCLC cell lines to Plk1 inhibition 
whereas MET makes cell lines more resistant. Mesenchymal cells are more sensitive 
to PLK1 inhibition than epithelial cells using isogenic human NSCLC models.   (A) 
Forced expression of miR-200 led to increased E-cadherin expression and decreased 
vimentin expression as determined by Western blotting and to resistance to volasertib 
as measured by MTT assay. Induction of a mesenchymal phenotype using ZEB1 
expression (B) or 5 ng/mL TGF-β (C) led to volasertib sensitivity and increased 
volasertib-induced apoptosis. *, P < 0.05 compared to control or as indicated. 
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Large scale screen of NSCLC cell lines to Plk1 inhibitors 
Previous studies have shown Plk1 inhibitors to have broad antitumor activity in 
diverse set of cancer cell lines (46, 58, 61, 94, 95) and mouse xenografts (49, 96). The 
GDSC (34) and CCLE (33) databases demonstrated that NSCLC cell lines responded 
to Plk1 inhibitors (Figure 6). However, it had not been shown in a large panel of NSCLC 
cell lines. In our study, we screened over 50 NSCLC cell lines with BI2536, volasertib, 
and GSK461364 by MTT and CellTiter-Glo. We observed that Plk1 inhibition led to 
decreased viability in all cell lines, but was substantially different in the sensitive cell 
lines compared to the resistant cell lines (Figure 6). We differentiated sensitive cell lines 
and resistant cell lines based on the inhibition of 70% of cell growth (IC70) being 
reached prior to the Cmax dose. After screening all the cell lines with the three Plk1 
inhibitors, we found that a smaller subset of cell lines were either sensitive to all three 
inhibitors or resistant to all three inhibitors. This agrees with previous clinical studies 
that have shown low response rates to Plk1 inhibition in solid tumors (35, 46, 58, 61). 
We then proceeded to analyze correlations of Plk1 inhibitor sensitivity and potential 
candidate biomarkers from literature. 
Plk1 inhibitors have been approved for use in acute myeloid leukemia (AML) (58, 
95). One of the hallmarks of AML is that it has a high mitotic rate (97), meaning it has a 
short doubling time. Volasertib has been shown to be highly effective as single agent in 
AML (58). We studied if cell doubling time plays a role sensitivity because Plk1 affects 
the cell cycle, and cells that divide faster will go through the cell cycle more times than 
slower growing cells during the assays. Theoretically, the cells with shorter doubling 
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times would therefore be in G2 more frequently, causing them to be more vulnerable to 
Plk1 inhibition. This pattern is observed in regards to chemotherapy drugs targeting the 
S phase of the cell cycle, as seen by methotrexate (98).Based on the doubling time of 9 
(5 resistant, 4 sensitive) NSCLC cell lines, it appears doubling time does not correlate 
with sensitivity to Plk1 inhibition. This may have been due to the low absolute number of 
NSCLC cell lines used in the analysis.  
Previous studies had implicated TP53 and KRAS mutations as predictive 
biomarkers of Plk1 inhibition sensitivity. In cancer cells with p53 mutations or low 
expression of the protein, depleting Plk1 led to apoptosis following cell cycle arrest and 
spindle checkpoint activation (31, 53, 60). Additionally, knockdown of Plk1 preferentially 
reduced the survival of p53 deficient, oncogenic transformed cells and tumor growth 
(54). In our study, we tested correlation of TP53 mutational status with Plk1 inhibitor 
sensitivity, but found no significant correlation was found. This agrees with another 
study in which no significant different cytotoxic response between cancer cells with and 
without functional p53 was observed in colon, breast, lung, and cervical cancer cell lines 
after Plk1 depletion (99). 
 It has been suggested that KRAS mutant cells are sensitive to Plk1 inhibition, 
and it has been observed that KRAS G13D mutant colorectal cancer cell lines, 
increased cell death was observed after Plk1 depletion and inhibition (52). Due to the 
number of cell lines with only KRAS mutations being low, we put the NRAS and KRAS 
mutant cell lines in one group, the RAS mutant lines. The RAS mutant cell lines 
correlated with sensitivity for both BI2536 and volasertib (Table 3). To further 
characterize KRAS mutants, we applied an established KRAS dependency signature to 
99 
 
KRAS mutant NSCLC cell lines (64). KRAS-dependent NSCLC cell lines, defined as 
those that undergo apoptosis when KRAS is knocked down, exhibit classical epithelial 
morphology, whereas KRAS-independent cells display a mesenchymal phenotype (64).  
In unsupervised analysis, KRAS-independent cell lines clustered in the sensitive group 
for GSK461364 but not for the other 3 groups (Figure 17). Our data suggests that the 
response of KRAS mutant cell lines may depend on the inhibitors being used as they 
have different pharmacological properties. Additionally, the grouping the NRAS and 
KRAS mutant lines may have affected the correlations as they have different biological 
properties.  
 There have not been studies which examine correlation of basal gene and 
protein expression to a large panel of cell lines to Plk1 inhibition. As mentioned above, 
potential candidate biomarkers were not significantly correlated to response to Plk1 
inhibition. To determine why NSCLC cell lines had diverse sensitivities to Plk1 inhibition, 
we examined the relationship between drug sensitivity and baseline gene and protein 
expression in four groups of cell lines: BI2536-sensitive/resistant, volasertib-
sensitive/resistant, GSK461364-sensitive/resistant, and the universal cell lines. We 
found that the expression levels of several genes and proteins correlated with drug 
sensitivity (Table 4,5). E-cadherin and β-catenin were consistently expressed at higher 
levels in the resistant lines, while DNA-dependent protein kinase catalytic subunit (DNA-
PKcs) and thymidylate synthase were consistently overexpressed in the sensitive lines. 
The correlation of high E-cadherin expression with resistance to Plk1 inhibition was true 
for all three inhibitors, as well as the universal cell lines (Figure 20). The correlation with 
E-cadherin had not been previously reported. One link which has been established was 
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in the KRAS dependent cell lines which demonstrated less sensitivity to Plk1 depletion 
and inhibition compared to KRAS independent colon cancer cell lines. These KRAS 
dependent cells exhibited classical epithelial morphology (52, 64). Additionally, DNA-
PKcs synthase has been reported to associate with Plk1 to ensure proper chromosomal 
separation in preparation in anaphase (100). Additionally, β-catenin has been reported 
to be a substrate of Plk1 and is associated with signaling involved in chromosomal 
segregation, and is involved in cell-cell adhesion and EMT (101, 102). 
Biological effects of Plk1 inhibition 
Previous studies had used colony formation assays to assay for cell proliferation 
effects of Plk1 inhibition in glioma and medulloblastoma cells (99, 103). As another 
measure of proliferation, we analyzed colony formation, after pulse treating cells with 
volasertib and then continued culturing cells (Figure 10). This assay is distinct from the 
MTT as we are not exposing the drug to the cells for a prolonged period. Both total well 
area and average colony area decreased significantly in the sensitive cell lines 
compared to the resistant cell lines, indicating a greater decrease in proliferation in the 
sensitive cell lines. The result mirrored the results from the MTT assays, leading us to 
believe that the sensitive cells undergo an irreversible inhibition of proliferation 
compared to the resistant cells. The results agreed with previous findings in which 
diverse sensitivities were observed through the colony growth after Plk1 inhibitor 
treatment (94, 103).  
We observed that some of the dose response curves increased upward at higher 
concentrations of the drug, representing increased cell number (Figure 6). This has also 
been previously by Raab, et al. at which they also saw increased cell number at very 
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high doses in HeLa cells (104). This may be resulting from the off-target effects of the 
inhibitors, which also target tumor suppressors Plk2 and 3 (30). A large scale 
proteomics screen done by the same group identified DAPK as a target which is 
targeted by Plk1 inhibition and allows for survival of cells with genetic aberrations (104). 
Thus, it is possible that in this study that the drugs are inhibiting tumor suppressors 
such as DAPK at high concentrations.   
To determine whether the inhibitors were truly inhibiting Plk1 in cell lines, we 
looked at the expression of Plk1 targets in NSCLC cell lines. In our work, we 
demonstrated that mitotic substrates including Myt1 and indirectly CDK1 were inhibited 
by Plk1 inhibitors in both sensitive and resistant cells (Figure 7). Additionally, cyclin B 
levels increased following Plk1 inhibitor treatment. This was expected as the 
proteasomal degradation of cyclin B is Plk1 dependent. However, there was difference 
in the inhibition of phospho-TCTP at Ser46, which is a substrate involved in the spindle 
assembly checkpoint and chromosomal separation (42). This may suggest a possible 
resistance mechanism, suggesting the distinct biological differences we observe are 
occurring at the spindle checkpoint stage. Resistant cells appear to be able to bypass 
Plk1 spindle checkpoint signals and continue dividing with aberrant chromosomal 
separation. Previous studies have shown that Plk1 inhibition leads to polyploid cells and 
multipolar spindles (36, 41, 45, 49, 54, 58, 61). Additionally, assaying for Plk1 activity at 
longer timepoints (Figure 9) exhibited similar results. This may additionally suggest that 
the target may not be sufficiently inhibited in resistant cell lines at longer time points, 
allowing cells to start proliferating again. This is in agreement with what we observed in 
the colony formation assays.  
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Sensitive cell lines appeared to undergo cell cycle arrest, had increased sub-G0 
population, and underwent apoptosis (Figure 11-13). In contrast, resistant cell lines had 
an increase in cells with 4N DNA content, increased number of polyploid cells, and 
underwent less apoptosis compared to the sensitive cell lines. We are unable to 
distinguish if the 4N cells were in G1 or G2 of different cell cycles as we also observe 
increased polyploid cells, especially with our resistant cells. Additionally, we observed 
an increase in polyploid cells in resistant cells using both through cell cycle analysis and 
microscopy. This may be a sign of cells undergoing a mitotic catastrophe. Here, cells 
would be able to bypass the spindle assembly checkpoint and divide. Cells which 
bypass this checkpoint would now be aneuploid due to improper chromosomal 
segregation. These cells are able to go into the next cell cycle and continue dividing 
(105). When comparing to Plk1 knockdown in the same cell lines, the same 
accumulation of 4N cells was seen after the Plk1 knockdown. There was significantly 
more apoptosis in the cells after knockdown compared to inhibition; however, the results 
mirrored those from the Plk1 inhibition where we see more apoptosis in that the 
sensitive cell lines compared to the resistant cell lines, confirming the effects of the 
inhibitors in NSCLC cell lines were mainly Plk1-driven.  
One mechanism which may be leading to this resistance is the expression of 
ABC transporter proteins involved in multi-drug resistance. Plk1 inhibitor resistance has 
been implicated with the expression of ATP Binding Cassette transporter proteins which 
are involved in multi-drug resistance mechanisms (46, 90). We evaluated basal gene 
expression of ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 with 
sensitivity to the three Plk1 inhibitors. No statistically significant correlation was found 
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(Figure 19). Although ABC transporter mRNA levels did not correlate, there is evidence 
to suggest that these proteins are highly regulated at the translational level (106, 107). 
In the case of the dose-dependent response Western blots, we saw substrate 
reactivation at high concentrations for GSK461364 (Figure 7). When we examined 
protein expression of different ABC transporters, we saw induction of expression of 
ABCB1 and ABCC10 (Figure 8). There have been previous reports of ABC transporters 
being involved in a possible resistance mechanism for this particular inhibitor (31, 90). 
Previous studies had demonstrated that treatment of GSK461364 in ABCB1 
overexpressing ovarian cancer cell lines led to the efflux of transporter substrate dyes 
(90, 106, 107). Assaying for activity through dye efflux would help us understand if 
inhibitors are substrates of these proteins. Additionally, the combination of Plk1 
inhibitors and MDR1 inhibitors may lead to sensitization of resistant cells if this is the 
major issue. 
Plk1 inhibition and EMT 
 After analyzing gene and protein expression, it was evident that EMT related 
proteins are highly correlated with Plk1 inhibitor sensitivity in NSCLC cell lines.  E-
cadherin expression was highest in the resistant cell lines. In 2013, Byers et al 
published an EMT gene signature (80). The signature is based on a set of 76 genes 
related to EMT which were validated using gene expression from four platforms in 
NSCLC cell lines and tumor samples from the BATTLE study. The signature was able to 
predict resistance to EGFR inhibitors and PI3K/Akt inhibitors. We discovered that 
NSCLC lines with high EMT scores (more mesenchymal cell lines) are more sensitive to 
all three Plk1 inhibitors.  In addition, forced induction of an epithelial phenotype resulted 
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in drug resistance, and forced induction of a mesenchymal phenotype increased drug 
sensitivity. Recent publications have demonstrated that the miR-200-ZEB1 axis is 
crucial in the regulation of the EMT phenotype (93, 108, 109). It was also seen that the 
manipulation of EMT related transcription factor ZEB1 and miR-200, which are 
repressors and activators of E-cadherin expression respectively, slightly reversed 
sensitivity or resistance. However, only knocking down E-cadherin using siRNA did not 
change sensitivity to the Plk1 inhibition. Treatment of cells with TGF- β is also known to 
induce EMT through the activation of Smad proteins and other EMT-related pathways 
(65, 66, 73, 74, 109). Inducing EMT through treatment with TGF- β resulted in a 
significant increase in apoptosis in a universal resistant cell line H358.  
Tight-junction and Rho signaling pathways are also related to EMT, and these 
pathways were enriched, as seen by analyzing the pathways altered in our differential 
gene expression (Table 6).  Tight junctions are an extremely important component of 
the signaling pathways that regulate epithelial proliferation and differentiation (110-112). 
Additionally, Rho family GTPases are essential for epithelial cell polarity, tight-junction 
assembly, and regulation of the actin cytoskeleton (113). It is also interesting to note 
that one of the ways TGF- β facilitates EMT in non Smad related processes is by 
regulating Rho GTPases (65).  
No previous studies had linked mesenchymal phenotypes to Plk1 inhibitor 
sensitivity. However, previous studies had shown that breast cancer and glioblastoma 
cell lines were more susceptible to Plk1 inhibition; these cell lines are known to be more 
mesenchymal (50, 94). The change in morphology appears to dictate the sensitivity and 
resistance, as evidenced by our isogenic models, in which we were able to induce cells 
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to become either more epithelial or more mesenchymal. However, this may be a 
secondary effect of the alteration of several pathways rather than the primary 
mechanism. For example, when we manipulated the expression of E-cadherin through 
siRNA, we did not see significant changes in apoptosis. Additionally, ZEB1 and miR-200 
primarily affect EMT status through modulation of E-cadherin expression (93). Although 
we saw changes in the MTT assays using these models, we did not observe significant 
differences in apoptosis after treatment compared to controls.  However, TGF- β 
induced EMT resulted in cells undergoing significantly more apoptosis compared to the 
parental cell lines. TGF- β  is known to affect several signaling pathways, not just EMT 
related, which may play a role in affecting sensitivity. 
Conclusions 
As we saw, the NSCLC cell lines demonstrated diverse sensitivities to Plk1 
inhibition. Sensitive and resistant cell lines exhibited different biological responses to 
Plk1 inhibition. Sensitive NSCLC cell lines undergo significantly more apoptosis 
compared to resistant cell lines. Gene and protein expression profiles showed that 
expression of specific sets of genes and proteins, especially those related to EMT, 
significantly correlate with response to Plk1 inhibitors, which may be used as predictive 
biomarkers. Finally, modulation of EMT status in NSCLC cell lines leads to changes in 
sensitivity.  
The major implications of this study are the potential for clinical benefits. As we 
chose the most clinically relevant Plk1 inhibitors, our findings have translational impact. 
Most mesenchymal type cancers are resistant to therapies (114, 115). Additionally, 
EMT is one of the mechanisms leading to loss of oncogene addiction (116). More 
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mesenchymal tumors usually have worse prognosis and represent an unmet need in 
terms of today’s cancer therapy. If Plk1 inhibitors are effective in mesenchymal tumors 
in vivo, this may provide a possible therapeutic benefit for those patients who may suffer 
from this disease. Additionally, it would be interesting to see if the diverse biological 
responses we observed were distinguished based on EMT status.  
One limitation of our study is the poor correlation of the effects of the two 
Boehringer Ingelheim compounds (BI2536 and volasertib) with the effects of 
GSK461364. The differences in the drugs’ effects may be attributed to differences in the 
drugs’ selectivities (GSK461364 is more selective against Plk1). Similar inconsistencies 
have been reported in two large-scale pharmacogenomic studies, where genomic data 
were well correlated between the studies, but responses of the drugs highly discordant 
(117). Additionally, we noted that in some cell lines, higher drug concentrations had less 
of an effect on cell viability than intermediate concentrations (Figure 6). Additionally, in 
our cell screening assays, the MTT and CellTiter-Glo assays do not distinguish if cells 
are in cell cycle arrest or are undergoing apoptosis (118). These assays may not 
completely reflect the cell growth of the cells following Plk1 inhbition.   
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Future Directions 
Although we clearly demonstrated that mesenchymal NSCLC cell lines were 
more sensitive to Plk1 inhibition, future studies should focus on the mechanisms that 
lead to Plk1-inhibitor induced apoptosis in mesenchymal cells. To study this 
mechanism, we could use unbiased methods to identify potential mechanisms which 
are contributing to the link between EMT and the Plk1 inhibitor-induced apoptosis. As 
we have been able to establish isogenic models in which we are able to reverse 
sensitivity and resistance, we could run gene expression arrays and RPPA pre and post 
treatment to determine which signaling pathways are differentially regulated in the 
models. In this case, we are not focused to a singular pathway to study, but rather 
several different pathways which may contribute to the effects we are seeing. As we 
saw, induction of EMT through TGF-β sensitized the cells and MET through miR-200 
made cells more resistant. We would be able to use these models and either use Plk1 
inhibitors or siRNA against Plk1 to see which pathways are differentially regulated. 
Additionally, we saw that tight junction signaling was enriched in our resistant cell 
lines based on our gene expression data. This may be an area of study in which we 
could manipulate the genes regulating this pathway in resistant cell lines to see if 
alteration may lead to a change in sensitivity. As we know, proteins related to tight 
junction signaling are related to epithelial cell polarity and adhesions, especially in the 
case of claudins and occluding, which were differentially expressed. The Rho-family of 
GTPases also is implicated in the regulation of these cell-cell junctions, and may be 
another area of study. Another major target we could study, in terms of mechanism is 
role of β-catenin. The expression of β-catenin, both at the mRNA and protein level 
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highly correlated with resistance. As has been reported, it is related to tight junction 
signaling, cell polarity, and cell-cell junctions. Additionally, it has been reported that β 
catenin and Wnt signaling play important regulatory roles in the nucleus where it is 
important in centrosomal separation (102), interacting with NEK2, which is a substrate 
of Plk1 (101).  
Plk1 may synergize with DNA damaging agents such as chemotherapy and 
radiotherapy to kill cancer cells (95, 119). In this regard, in the differential gene 
expression patterns, sensitive cells lines had altered DNA damage-related proteins 
compared to resistant lines. This may open up new directions to study in terms of 
combinations. We may also be able to combine DNA damaging agents such as cisplatin 
or gemcitabine with Plk1 inhibitors. If the resistant cell lines are able to continue cycling 
and go into subsequent cell cycles with aneuploidy, we may be able to use drugs 
targeting the S phase to  target cells which are resistant to Plk1 inhibition. 
We observed that some EGFR tyrosine kinase inhibitor acquired resistant cell 
lines became more mesenchymal and more sensitive to Plk1 inhibition. Three different 
cell lines had been tested, and of these, two became more mesenchymal to acquire 
resistance to EGFR tyrosine kinase inhibitor erlotinib (preliminary data, not shown). 
HCC827 and HCC4006 parental cell lines were among those which were universally 
resistant in our screen of the Plk1 inhibitors. In these resistant clones, it has been seen 
that Axl kinase expression has been elevated. This has been reported as a potential 
mechanism leading to mitotic kinase inhibitor vulnerability in conjunction with Axl 
inhibitors by Dr. Jeff Settleman’s group (120). Additionally, the isogenic model in which 
TGF-β was used to change the morphology of H358 cell line into a mesenchymal cell 
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line was shown to have significant increase in apoptosis in our study. It has been 
reported that TGF-β induced H358 is also resistant to erlotinib and had increased Axl 
(120). This may be another potential area of study in which we can determine if 
acquired resistance to erlotinib through EMT and increased Axl may contribute to Plk1 
inhibitor sensitivity through the EGFR pathway. There also may be the potential for 
combination studies with erlotinib to sensitize cell lines which are resistant to erlotinib 
with a Plk1 inhibitor such as volasertib. 
Our in vitro studies using Plk1 inhibitors have shown a strong correlation with 
EMT scores and E-cadherin alone. E-cadherin expression may present a simple 
biomarker for Plk1 inhibitor response. To test this hypothesis, the next logical step 
would be to move to in vivo models, using cell line xenografts with diverse EMT status. 
However, more telling in terms of translational relevance, it would be interesting to study 
the response in patient derived xenograft (PDX) or genetically engineered mouse 
models. The study of Plk1 inhibitor response in PDX models would be a stronger tool as 
these models are closer to human tumors. We may be able to establish PDX models to 
be able to treat tumors in mice and determine the EMT status of these tumors to see if 
the relationship of EMT status and Plk1 inhibitor sensitivity holds in this setting.  
If the results from such in vivo studies would yield promising results, we may be 
able to test our conclusions in a clinical trial with FDA approved Plk1 inhibitors 
(volasertib). E-cadherin expression may serve as a simple biomarker to predict 
response to Plk1 inhibitors in NSCLC patients. Biopsies taken from patients may be 
analyzed for EMT biomarkers, such as E-cadherin, and patients can be randomized into 
different groups. In the clinical setting, mesenchymal tumors are typically more resistant 
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to standard therapeutic regimens. If our hypothesis holds, then Plk1 inhibitors will be a 
choice for patient treatment modalities.   
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